What Antibiotics Treat Pelvic Inflammatory Disease?

Pelvic inflammatory disease (PID) is treated with combinations of antibiotics, not a single drug, because the infection is almost always caused by a mix of different bacteria at the same time. The most common outpatient approach pairs an injectable cephalosporin with a two-week course of oral doxycycline, and many clinicians now add metronidazole as a third drug. Which specific regimen you receive, how long you take it, and whether you’re treated at home or in a hospital all depend on the severity of the infection, but the guiding principle is the same: the antibiotic combination must be broad enough to cover everything likely growing in the upper reproductive tract.

Why PID Requires Multiple Antibiotics

PID is widely recognized as a polymicrobial infection. The sexually transmitted bacteria Neisseria gonorrhoeae and Chlamydia trachomatis are present in many cases, but they are rarely acting alone. Anaerobic and facultative bacteria, many of them similar to the organisms involved in bacterial vaginosis, are frequently recovered from the upper genital tract during PID episodes.¹ Older surgical and culture-based studies found that anaerobic cocci and Bacteroides species were among the most frequent pathogens, alongside gonorrhea.² More recently, Mycoplasma genitalium has been identified as another likely contributor.¹

Because so many different organisms can be involved, a single antibiotic that targets only chlamydia, or only gonorrhea, would leave a large chunk of the infection untouched. That’s why every major guideline calls for broad-spectrum coverage: the antibiotics prescribed need to work against sexually transmitted organisms, anaerobes, and ideally mycoplasmas all at once.³ In practice this means you’ll almost always receive at least two drugs, each handling a different slice of the microbial spectrum.

The Standard Outpatient Regimen

Most PID is mild to moderate and can be treated at home with oral antibiotics, usually after a single injection given in the clinic. The backbone of the recommended outpatient regimen in the United States is a one-time intramuscular shot of ceftriaxone (a cephalosporin active against gonorrhea) followed by 14 days of oral doxycycline (a tetracycline that covers chlamydia and several other organisms). The CDC guidelines have long endorsed this two-drug combination, and many international guidelines mirror it closely.

To that two-drug core, many clinicians now add oral metronidazole for the full 14-day course. Metronidazole is a nitroimidazole antibiotic with strong activity against anaerobic bacteria, the same organisms often implicated in bacterial vaginosis. A randomized controlled trial comparing ceftriaxone plus doxycycline with and without metronidazole found that adding it was well tolerated and resulted in better clearance of anaerobes from the endometrium, a reduction in M. genitalium, and less pelvic tenderness at follow-up.⁴ Based on that evidence, the recommendation to include metronidazole has strengthened in recent years.

European guidelines from the International Union against Sexually Transmitted Infections (IUSTI) also list oral moxifloxacin as an alternative outpatient option. Moxifloxacin is a fluoroquinolone with relatively broad coverage on its own, including some activity against M. genitalium.⁵ The CDC does not list moxifloxacin as a first-line choice, partly because fluoroquinolone resistance in gonorrhea is an ongoing concern. So if you see moxifloxacin mentioned in a treatment guideline, it is typically positioned as a backup rather than the default.

When You Need Hospital-Based Antibiotics

Some cases of PID are severe enough to warrant intravenous antibiotics in a hospital. Situations that usually tip the decision toward admission include a tubo-ovarian abscess visible on imaging, failure to improve after a couple of days of oral antibiotics, inability to tolerate oral medications because of nausea and vomiting, pregnancy, or a clinical picture severe enough that a surgical emergency cannot be ruled out.

Two parenteral (intravenous) regimens are recommended most often:

Cephalosporin plus doxycycline: Either cefotetan or cefoxitin is given intravenously, paired with oral or IV doxycycline. Both cephalosporins have shown clinical cure rates above 90 percent, with complete eradication of gonorrhea and chlamydia from the endometrium at follow-up.⁶
Clindamycin plus gentamicin: Clindamycin covers anaerobes and some gram-positive organisms, while gentamicin (an aminoglycoside) handles gram-negative bacteria. This combination has been a workhorse in PID treatment for decades, and retrospective data support its effectiveness.⁷

With either inpatient regimen, you typically switch to oral antibiotics once you’ve improved clinically, usually after 24 to 48 hours without fever. The oral step-down is most commonly doxycycline, often with metronidazole added, to complete a full 14-day course.

Is One Regimen Clearly Better Than Another?

Probably not, at least based on available head-to-head data. A Cochrane-derived systematic review of randomized trials comparing different PID antibiotic regimens found no clear evidence that any one combination was safer or more effective than the alternatives. Specifically, azithromycin versus doxycycline, quinolone versus cephalosporin, and clindamycin plus aminoglycoside versus either quinolone or cephalosporin all showed comparable cure rates for both mild-moderate and severe PID.⁸ The review also noted no conclusive advantage for regimens that included a nitroimidazole like metronidazole over those relying on other drugs with anti-anaerobic activity.

That might seem to contradict the randomized trial showing benefits from adding metronidazole. The Cochrane analysis pooled older and smaller trials and looked at a slightly different question: whether any nitroimidazole use improved overall cure rates, whereas the more recent trial measured specific microbiological endpoints like anaerobe clearance and tenderness reduction.⁴ In practice, many infectious-disease specialists now favor including metronidazole because the downside is small and the upside, particularly in patients with concurrent bacterial vaginosis, appears real. But the evidence base still isn’t as rock-solid as you might expect for such a common infection. The Cochrane authors explicitly called for more trials to settle the question.⁸

The Mycoplasma genitalium Problem

One of the trickier aspects of PID treatment is that the standard regimens may not reliably cover Mycoplasma genitalium. This organism lacks a cell wall, which makes it inherently resistant to beta-lactam antibiotics like cephalosporins. And several lines of evidence suggest that it is also resistant to many frequently used PID regimens: treatment failure has been documented specifically after cefoxitin plus doxycycline therapy in women with clinically suspected PID.⁹

The antibiotics with the best activity against M. genitalium are macrolides (particularly azithromycin) and certain fluoroquinolones (like moxifloxacin). But macrolide resistance in M. genitalium has been climbing rapidly in many countries, complicating the picture further. Some clinicians now test for M. genitalium using molecular tests when PID fails to respond to the standard regimen, then tailor the follow-up antibiotics accordingly. This is not yet universal practice, but the awareness is growing. If you’ve been treated for PID and your symptoms haven’t improved after a few days of antibiotics, M. genitalium is one of the organisms your doctor may start thinking about.

Side Effects and Finishing the Full Course

A 14-day course of oral antibiotics is a long time, and side effects are common, particularly gastrointestinal symptoms like nausea, stomach upset, and diarrhea. In the randomized trial comparing metronidazole versus placebo alongside ceftriaxone and doxycycline, roughly 80 to 90 percent of women in both arms reported at least some adverse event, and GI complaints were the most frequent type. Importantly, the rates were similar whether or not metronidazole was part of the regimen.¹⁰ That means much of the nausea you feel during PID treatment is attributable to doxycycline itself, a drug well known for causing stomach irritation, especially when taken without food.

Adherence to the full 14-day course hovers around 80 to 85 percent in clinical trials, which is actually better than many outpatient antibiotic regimens but still means roughly one in five women don’t finish.¹⁰ A few practical tips that help: take doxycycline with a full glass of water and some food, stay upright for at least 30 minutes afterward to reduce esophageal irritation, and avoid metronidazole with alcohol (the combination can cause severe nausea and vomiting). If you can’t keep the pills down at all, that’s a reason to contact your doctor, since inability to tolerate oral medication is one of the criteria for switching to intravenous treatment.

Why Starting Treatment Quickly Matters

PID is one of the infections where the threshold for starting antibiotics is deliberately kept low. Doctors are trained to begin empiric treatment as soon as there is a reasonable suspicion of PID, even before lab results come back, because waiting for confirmation risks real harm. The concern isn’t primarily about the acute infection itself, which is painful but usually manageable. It’s about the long-term damage that untreated or under-treated inflammation can cause to the fallopian tubes and surrounding structures.

A study that tracked women after PID episodes found that those who delayed seeking care were roughly three times more likely to experience infertility or ectopic pregnancy compared with women who sought treatment promptly. The association was strongest in women infected with chlamydia: among those who delayed, about 18 percent developed impaired fertility, while none of the women who sought care promptly suffered known long-term consequences.¹¹ These numbers are from a single study and the confidence interval was wide, but the direction of the finding is consistent with everything else we know about tubal scarring: the longer the infection smolders, the more damage accumulates.

This is also why guideline deviations are a concern in clinical practice. Surveys and chart reviews have consistently found that real-world prescribing doesn’t always match published guidelines.¹² Sometimes that means a narrower-spectrum antibiotic than recommended, sometimes it means a shorter course. If you’re treated for PID and the regimen you receive doesn’t match what you’ve read here, it’s worth asking your provider whether the full recommended combination was considered.

Treating Your Sexual Partner

Antibiotics alone won’t prevent PID from coming back if the sexually transmitted organisms that triggered it are still circulating between you and your partner. All recent sexual partners, typically anyone you’ve had sex with in the 60 days before symptoms started, should be tested and treated for chlamydia and gonorrhea regardless of whether they have symptoms. Most men carrying these infections are asymptomatic, so the absence of symptoms in a partner doesn’t mean much.

In some jurisdictions, doctors can provide prescriptions for your partner without seeing them directly, a practice known as expedited partner therapy. This approach has been shown to reduce reinfection rates in chlamydia and gonorrhea broadly, and since reinfection is one of the strongest risk factors for another PID episode, it matters. You should avoid sexual intercourse until both you and your partner have completed the full course of treatment and any follow-up testing. That waiting period can feel inconvenient when you’re already dealing with a two-week antibiotic course, but reinfection during treatment essentially resets the clock and raises the risk of complications.

PID in People With an IUD

A common question is whether an intrauterine device needs to be removed if you develop PID. The short answer is that removal is not routinely required. The slightly elevated risk of PID associated with IUDs is concentrated in the first few weeks after insertion, when bacteria can be introduced during the procedure, and the device itself doesn’t meaningfully contribute to ongoing infection once it’s been in place for a while.

Current guidelines generally recommend starting antibiotic treatment with the IUD in place and reassessing after 48 to 72 hours. If you’re not improving, your doctor may consider removal as one of several next steps. A Cochrane review looking specifically at the question of immediate versus delayed IUD removal in women with PID found no randomized controlled trials evaluating the question, meaning there is genuinely no high-quality evidence telling us whether pulling the IUD early helps, hurts, or makes no difference.¹³ In the absence of that evidence, the default has been to leave the device in unless there’s a specific reason to remove it, which avoids the loss of contraception while treating the infection.

Differences Between CDC and European Guidelines

If you compare the U.S. CDC guidelines with the European IUSTI guidelines side by side, the core first-line regimens look quite similar: a cephalosporin injection, doxycycline, and metronidazole for outpatients; cephalosporin-based or clindamycin-based IV regimens for inpatients. The differences show up mostly in the alternatives. The IUSTI guidelines include oral moxifloxacin as an alternative outpatient regimen, reflecting European comfort with fluoroquinolones in this setting, while the CDC avoids recommending fluoroquinolones for PID because of high gonorrhea resistance rates in the United States.⁵ There are also minor differences in alternative inpatient regimens.

For most patients these guideline differences are academic. Your treatment will follow whichever guideline is standard in your country, and both sets of recommendations are based on the same core evidence. Where the distinction matters is when standard treatment fails. If you don’t respond to the usual cephalosporin-doxycycline combination, your doctor may look to alternative regimens, and knowing that other reputable guidelines endorse options like moxifloxacin can open a conversation about next steps. It’s also worth knowing that cure rates across all recommended regimens, while generally good, do show some variation, and no regimen has demonstrated a perfect track record in clinical trials.

When Symptoms Don’t Improve

You should expect to feel at least somewhat better within 48 to 72 hours of starting antibiotics. If pelvic pain, fever, or tenderness haven’t improved at all by then, your doctor will want to reconsider the diagnosis and the treatment plan. Failure to respond can mean a few things: the bacteria involved may not be susceptible to the chosen antibiotics, there may be a tubo-ovarian abscess that needs drainage, or the original diagnosis may not have been PID at all. Conditions like appendicitis, ovarian torsion, and endometriosis can mimic PID closely enough to fool even experienced clinicians.

For true antibiotic failure, the next move typically involves imaging (usually a pelvic ultrasound or CT scan if not already done) and a change in the antibiotic regimen. Switching from an outpatient oral regimen to intravenous antibiotics in the hospital is common at this stage. If M. genitalium hasn’t been tested for, this is often when it gets checked. And if an abscess is identified, it may require percutaneous drainage or, rarely, surgery. The key takeaway is that not improving on antibiotics is not something to ride out at home. Going back to your provider at the 48-to-72-hour mark is part of the treatment plan, not a sign that something has gone unusually wrong.

1
PubMed Central. Treatment of acute pelvic inflammatory disease
2
PubMed. Bacterial synergy in pelvic inflammatory disease
3
PubMed. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease
4
Clinical Infectious Diseases. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease
5
PubMed. A review of antibiotic therapy for pelvic inflammatory disease
6
PubMed. Treatment of hospitalized patients with acute pelvic inflammatory disease: comparison of cefotetan plus doxycycline and cefoxitin plus doxycycline
7
PubMed Central. The Combination of Clindamycin and Gentamicin Is Adequate for Pelvic Inflammatory Disease: A Retrospective Cohort Study
8
Sexually Transmitted Infections. Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials
9
PubMed Central. Mycoplasma genitalium: an emerging cause of pelvic inflammatory disease
10
Clinical Infectious Diseases. A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease – Section: Results
11
PubMed. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility
12
PubMed Central. Management of Pelvic Inflammatory Disease in Clinical Practice
13
PubMed Central. Removal of intrauterine device as part of the treatment for women with pelvic inflammatory disease